ClinicalTrials.gg
Not yet recruitingNCT07947901Updated Nov 19, 2026

Block-LC SGB Treatment Trial

A Phase 2 interventional study of Bupivacaine-HCl and Lidocaine in COVID -19, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's title name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
24th of 156
272 · median 53
Started
2026
with 12 others
Phase 2
48 of 195
11 open now
Primary completion
2029-04
later than 74 of 84 live
Registered
195th of 195
by date

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 24th largest by planned enrollment of the 156 interventional ones that give a count, is one of 13 that started in 2026, is one of 48 in phase 2, reaches primary completion later than 74 of the 84 other live ones, and was the 195th registered.

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (SGB or Sham) administered to adults with Long COVID (Figure 1) followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 at Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. Follow-up visits at weeks 12 and 26 allow for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures.

Read the detailed description

This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (Stellate Ganglion Block (SGB) or Sham) administered to adults with Long COVID followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 on Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. The inclusion of follow-up visits at weeks 12 and 26 allows for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures. The secondary objectives are 1) To compare the change in fatigue severity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 2) To compare the change in attention and working memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 3) To compare the change in processing speed and executive function from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 4) To compare the change in verbal fluency from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 5) To compare the change in learning and memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 6) To compare the change in orthostatic intolerance symptoms from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 7) To compare the change in functional capacity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 8) To evaluate safety in participants randomized to a series of two sets of bilateral SGB or sham Study Procedures.

03

Conditions studied

  • COVID -19

Browse trials for

Keywords

  • Block-LC
  • Long COVID
  • Multi-site
  • Phase 2
  • Randomized
  • Sham-Controlled
  • single-blind
  • Stellate Ganglion Block
04

In context

Post-Acute COVID-19 Syndrome Reclassified

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 272 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years, inclusive, at the time of consent.
  2. History of SARS-CoV-2 infection*a-d

    1. Shown by (1) a positive nucleic acid amplification test (NAAT) or antigen test,*b OR (2) meeting clinical criteria AND an epidemiologic link to a confirmed case.*c,d
    2. See Section 8.1, Visit 00A, for a list of acceptable documentation required to confirm past SARS CoV-2 infections.
    3. Clinical criteria is defined as either (1) acute onset of fever AND cough (influenza like illness); OR (2) acute altered/loss of taste or smell + one additional symptom including fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, or anorexia; OR (3) three or more symptoms, including fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, or anorexia.
    4. Epidemiologic link is defined as having contact (within 6 feet for at least 15 minutes) with someone sick with SARS-CoV-2 test-positive COVID-19 illness.
  3. Clinical evidence of Long COVID*a and Long COVID symptoms that cannot be attributed to another cause upon investigator review of medical history and evaluation prior to study entry. *b

    1. Participants must meet the 2024 NASEM definition for Long COVID.
    2. In the judgment of the investigator.
  4. Has a substantial reduction or impairment in ability to engage in pre-illness levels of activity (occupational, educational, social, or personal life) following COVID-19 illness.*a

    a. Based on symptom-specific criteria.

  5. Presents at least two of the primary symptoms of interest*a,f that cannot be explained by an alternative diagnosis in the judgment of a site investigator.

    1. Primary symptoms of interest are fatigue,*b cognitive difficulty,*c orthostatic intolerance,*d and PEM.*e
    2. Fatigue is defined by a previous clinical diagnosis or a mean score of >/= 4 total score on the Fatigue Severity Scale.
    3. Cognitive difficulty is defined by a previous clinical diagnosis or a T-score of \<40 on the PROMIS-29+2 Cognitive Function - Abilities subdomain.
    4. Orthostatic intolerance is defined by a previous clinical diagnosis or one question with a score > 2 on the Orthostatic Intolerance Questionnaire.
    5. PEM is defined by a previous clinical diagnosis or score of >/= 2 for severity and frequency for at least one applicable question on the Long COVID Symptom Screener.
    6. Symptoms must be "new" (i.e., onset during or following a COVID-19 illness) with a duration of at least 6 months and be present at the time of screening. Symptom(s) may fluctuate during trial, as long as they meet the above initial criteria.
  6. Has a PROPr score of \</= 0.35 on the screening PROMIS-29+ 2.
  7. Acceptable clinical screening laboratory evaluations.*a,b must be \<1.3 and must be >100,000 per microliter. Other screening laboratory evaluations must be within normal reference ranges or Grade 1 per the DAIDS Table with no clinical significance (NCS) per investigator's discretion.*c

    1. The screening labs will include CBC, Comprehensive metabolic panel, PT,INR, and PTT. (CBC includes , WBC (with differential), Hct, and Plt. Comprehensive metabolic panel includes blood glucose, blood urea nitrogen, creatinine, alkaline phosphatase, , aspartate aminotransferase, total , albumin, total protein, bicarbonate, chloride, sodium, potassium.)
    2. Additional screening labs to identify causes of fatigue unrelated to Long COVID: thyroid-stimulating hormone (TSH), free thyroxine (FT4), and vitamin B12.
    3. Clinical laboratory evaluations that are outside the site reference range, but not graded by the toxicity table, are not exclusionary unless deemed by an investigator. Values graded by the toxicity table to be Grade 2 or higher are considered exclusionary even if they fall within the site-specific normal reference range.
  8. Fluent in English or Spanish.
  9. Willing and able to provide before initiation of any study activities.
  10. Able to understand and agree to comply with all planned study activities*a and be available for all study visits in the randomized controlled portion of the study.

    1. Participants still may enroll if they are unable or unwilling to complete blood draw(s) for biomarkers. An initial blood draw for screening clinical laboratory assessments is required to be completed prior to randomization.
  11. Agrees to maintain*a,b non-study medications, vitamins, and supplements at current doses for the duration of the randomized controlled portion of the trial.*c

    1. Except as prescribed or instructed by their treating clinician.
    2. Agree to not begin other new over-the-counter (OTC) medications, vitamins, and supplements unless prescribed or instructed by their treating clinician.
    3. OTC pain relief is allowed (e.g., ibuprofen, NSAIDs, acetaminophen) and should be documented.
  12. Agrees to maintain non-pharmacological Long COVID therapies (e.g., vagal nerve stimulation, acupuncture) consistent*a for the duration of the randomized controlled portion of the trial.

    a. Except as instructed by their treating clinician.

  13. Agrees to adhere to all lifestyle considerations in Section 5.5 for the duration of the randomized controlled portion of the trial.
  14. Agrees to utilize electronic data capture for the e-Memory Aid and electronic PROs and have access to a device connected to the internet for completion.

Exclusion criteria

Exclusion Criteria:

  1. Known acute SARS-CoV-2 infection \<= 30 days from the time of randomization.
  2. Has received any previous autonomic or sympathetic blocks prior to randomization or plans to receive any non-study related autonomic or sympathetic blocks during the study intervention period.
  3. to SGB*a,b

    1. These include but are not limited to active infection at the injection site, bleeding disorders, current anticoagulation therapy, current dual antiplatelet therapy (single agent aspirin therapy is permitted), known allergies to local anesthetics, known vocal cord paralysis, phrenic nerve dysfunction or diaphragmatic paralysis, prior pneumonectomy, or other condition that, in the judgment of the proceduralist, would increase the risk of complications from SGB, including transient recurrent laryngeal nerve or phrenic nerve blockade.
    2. Any other condition that, in the judgment of the investigator, substantially increases the procedural risk of SGB (e.g., severe cardiopulmonary disease).
  4. Known clinically significant ophthalmologic condition(s)*a a. These include but are not limited to untreated or uncontrolled glaucoma, active retinal vascular disease or retinal ischemia, acute or incompletely treated retinal detachment, or another clinically significant ophthalmologic condition that, in the investigator's judgment, could be adversely affected by changes in ocular perfusion or could interfere with assessment of the expected ocular effects of SGB.
  5. History of major surgery,*a myocardial infarction, or cerebrovascular events*b \<=365 days of randomization.

    1. Major surgery refers to procedures associated with substantial physiologic stress, significant postoperative recovery, hospitalization before or following surgery, prolonged functional limitation, major fluid shifts, or blood loss, or clinically meaningful postoperative inflammatory or cardiopulmonary effects that could confound study outcomes or safety assessment. Examples include but are not limited to major thoracic, cardiac, abdominal, vascular, neurosurgical, transplant, or major orthopedic procedures (e.g., joint replacement or spine surgery). Minor outpatient procedures or minimally invasive interventions with rapid recovery and minimal systemic impact will not be considered major surgery unless deemed clinically significant by the investigator.
    2. Major cerebrovascular events include but are not limited to ischemic stroke, , intracerebral hemorrhage, subarachnoid hemorrhage, cerebral venous sinus thrombosis, carotid or vertebral artery dissection, or another clinically significant acute cerebrovascular event within 365 days before randomization. Participants with a known untreated, unsecured, or otherwise clinically significant intracranial or cervical vascular abnormality are excluded regardless of the date of diagnosis. These abnormalities include intracranial aneurysm, cerebral arteriovenous malformation, dural arteriovenous fistula, carotid or vertebral artery aneurysm or pseudoaneurysm, active arterial dissection, or another vascular abnormality that may increase the risk of SGB. Participants with definitively treated lesions may be considered eligible after documentation of stability and review by the site investigator and proceduralist.
  6. Intercurrent illness, acute systemic infection, or acute fever, or unresolved recurrent fever at the time of enrollment that would increase procedural risk or may confound the safety assessments.
  7. Planned elective surgeries during study participation.
  8. Clinical diagnosis of ME/CFS, autonomic dysfunction, or other infection-associated chronic conditions with an onset prior to the qualifying SARS-CoV-2 infection.
  9. Positive pregnancy test at Visit 00A/00B/00C or within 24 hours before SGB/Sham Study Procedure; or plans to become pregnant during the randomized controlled trial period.
  10. Breastfeeding at the time of randomization or has plans to breastfeed during the randomized controlled trial period.
  11. Is of and not using a highly effective method during the study intervention period (Visit 00A through Visit 12).
  12. Participation in another interventional clinical trial \<= 30 days of randomization or planned participation during the study intervention period (Visit 00A through Visit 12).
  13. Began a new medication, supplement, or vitamin, or changed doses of a medication, supplement, or vitamin \<= 30 days of randomization.
  14. Initiation/discontinuation of medications*a that could affect autonomic function, cardiovascular function, participant safety, or assessment of study outcomes \</= 30 days of randomization.*b,c

    1. Examples include beta-blockers, midodrine, fludrocortisone, ivabradine, pyridostigmine, droxidopa, clonidine, guanfacine, antihypertensive agents, antiarrhythmic agents, or other autonomic- or cardiovascular-modulating therapies.
    2. Participants receiving these medications are eligible provided they have remained on a stable regimen for at least 30 days before randomization.
    3. In the investigator's judgment.
  15. Use of the following supplements garlic, hawthorn, ginkgo, turmeric or curcumin, ginger, high-dose vitamin E, nattokinase, and serrapeptase \</= 30 days of randomization.
  16. Initiation \</= 30 days of randomization or planned initiation during the randomized controlled portion of the trial of non-pharmacologic autonomic interventions.*a

    a. Excluded interventions include vagal nerve stimulation, autonomic neuromodulation, acupuncture, or additional sympathetic or autonomic blocks that could increase procedural risk or confound safety assessment.

  17. Known active acute hepatitis or a history of chronic liver disease (known Class B or C) or known severe chronic kidney disease or kidney failure ( \< 30 ml/min/1.73 m2).
  18. Has known active infection, active infection, or uncontrolled (i.e., not on antiretroviral therapy (ART) or on ART but has detectable viral load).
  19. Has recent active (received chemotherapy or radiotherapy in the 12 months prior to informed randomization) or active malignancy at informed randomization.*a

    a. Individuals with non-melanoma skin carcinoma (basal or squamous cell skin cancer), or low-grade cervical squamous intraepithelial lesions, which are considered cured and not requiring ongoing therapy, may be enrolled at the discretion of the investigator.

  20. Diagnosed in the 3 months prior to randomization with a new medical condition,*a other than Long COVID, causing new or worsening fatigue that is unresolved at time of randomization.

    a. Medical conditions that could cause new or worsening fatigue include but are not limited to iron deficiency with or without anemia, hypothyroidism, infectious mononucleosis (Epstein-Barr Virus or cytomegalovirus infection), celiac disease, type 1 diabetes mellitus, adrenal insufficiency, cardiac disease (e.g., myocarditis, arrythmia, or cardiomyopathy), metabolic disease, renal disease, or a primary sleep disorder (e.g., obstructive sleep apnea, restless legs syndrome, narcolepsy, or parasomnia).

  21. Participants with known or suspected glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, based on medical record review and judgment of site investigator.
  22. Participants with known history of to study compounds lidocaine and bupivacaine (or other components of these compounds) or local anesthetics of the amide type.
  23. Participants with clinically significant cardiac conduction disease.*a,b

    1. Including but not limited to Stokes-Adams syndrome; Wolff-Parkinson-White syndrome; severe degrees of sinoatrial, atrioventricular, or intraventricular block in the absence of an artificial pacemaker; sick sinus syndrome; second- or third-degree atrioventricular block, or other conduction abnormalities that, in the investigator's judgment, increase procedural risk or interfere with interpretation of cardiovascular study outcomes.
    2. Presence of an implanted pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization device, or other implanted cardiac rhythm-management device.
  24. Clinically significant findings*a at baseline that may increase procedural risk.

    a. Including but not limited to: interval (QTc) >480 milliseconds (ms); newly identified atrial fibrillation or flutter, sustained supraventricular tachycardia, or ventricular arrhythmia; second-degree Mobitz II or third-degree atrioventricular block; ventricular pre-excitation, including Wolff-Parkinson-White pattern; Brugada pattern or another finding associated with clinically important ventricular arrhythmia; evidence of acute myocardial ischemia; or any other ECG abnormality considered clinically significant by the investigator or proceduralist.

  25. Any other Long COVID symptoms besides the primary symptoms of interest that, in the judgment of a site investigator, present as their primary/predominant symptom.
  26. Physical conditions*a that obscure relevant sonoanatomy, alter the anticipated needle trajectory, or otherwise increase the risk of SGB.*b

    1. These include anatomic abnormality, prior surgery, radiation therapy, mass, infection, or other condition involving the neck.
    2. In the judgment of the Study PI or Proceduralist.
  27. Any other circumstance, including medical conditions,*a,b medication use, or other factors that pose a safety risk*c for or interfere with the reliable assessment of trial endpoints.*d

    1. Medical conditions include but are not limited to uncontrolled or clinically unstable cardiovascular disease, including symptomatic arrhythmia, decompensated heart failure, unstable angina, hypertensive emergency or urgency, clinically significant hypotension, or another cardiovascular condition that, in the proceduralist's judgment, increases procedural risk, and active unstable or progressive major neurologic conditions.
    2. Of note, an abnormal vital sign alone is not exclusionary at baseline. However, the abnormal vital sign may be indicative of an updated exclusionary medical condition as described above.
    3. In the site investigator's or proceduralist's judgment.
  28. Inability to safely cooperate with the procedure and required monitoring, including inability to remain appropriately positioned or communicate new symptoms during and after SGB/Sham Study Procedure(s).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
272 participants (estimated)

Study arms

  • Active comparator
    Arm 1- SGB Participants

    Participants will receive paired bilateral SGB administered under ultrasound guidance at the anatomical target of cervical vertebrae C6-C7. A skin wheal of approximately 0.5-3 mL buffered plain 1% lidocaine hydrochloride injection will be placed at the needle entry site. A 21- to 30-gauge block needle will be inserted and advanced to the tissue plane containing the cervical sympathetic chain under real-time ultrasound guidance to deliver 10 mL of preservative-free plain 0.5% bupivacaine hydrochloride injection. N = 136

    Drug: Bupivacaine-HCl · Drug: Lidocaine

  • Sham comparator
    Arm 2- Sham Participants

    Participants will receive bilateral sham injections administered on the same schedule as the active arm. A skin wheal of 0.5-3 mL buffered plain 1% lidocaine hydrochloride will be placed at the needle entry site. To simulate the active SGB procedure, a 21- to 30-gauge needle will be inserted only subcutaneously and with no injected medication. N = 136

    Drug: Lidocaine

Interventions

  • DrugBupivacaine-HCl

    Bupivacaine hydrochloride injection (without epinephrine) is a long-acting amide-type local anesthetic commonly used for the production of local or regional anesthesia and analgesia in a variety of clinical settings, including surgical, obstetrical, and diagnostic procedures. It is typically administered via local infiltration, peripheral nerve block, or epidural or spinal routes in sterile isotonic solution formulations.

  • DrugLidocaine

    Lidocaine is a local anesthetic of the amide group. Intradermal lidocaine hydrochloride injection is a local anesthetic administered into the superficial layers of the skin. It is commonly used prior to minor procedures including the formation of an intradermal skin wheal. When administered intradermally, lidocaine hydrochloride produces localized numbness without affecting consciousness.

07

What researchers measure

Primary outcomes

  1. Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Preference (PROPr) score

    Time frame: Through 8 weeks after randomization

Secondary outcomes

  1. Change from baseline in orthostatic intolerance symptoms

    Change in the following measures, all scored as worsened, no change, or improved from baseline: Sustained increased heart rate (HR) (\>= 30 beats per minute (bpm) for 20+ year old or \>= 40 bpm for \< 20 year old) from supine HR or an absolute HR \>= 120 bpm during the first 10 minutes of standing of the Active Stand Test Sustained decreased blood pressure (BP) (\>=20 mmHg in systolic pressure or \>=10 mmHg in diastolic pressure) during the first 10 minutes of standing of the Active Stand Test Any documented orthostatic intolerance (OI) symptoms (dizziness, blurry vision, fatigue, headache, and body pain) documented during the first 10 minutes of standing of the Active Stand Test

    Time frame: Through 8 weeks after randomization

  2. Change in Digit-Span WAIS-IV total age-corrected scaled score

    Time frame: Through 8 weeks after randomization

  3. Change in Functional Capacity Questionnaire (FUNCAP27) total mean score

    Time frame: Through 8 weeks after randomization

  4. Change in Hopkins Verbal Learning Test-Revised (HVLT-R) total recall T-score

    Time frame: Through 8 weeks after randomization

  5. Change in HVLT-R retention % T-score

    Time frame: Through 8 weeks after randomization

  6. Change in Symbol Digit Modalities Test (SDMT) total T-score

    Time frame: Through 8 weeks after randomization

  7. Change in the Fatigue Severity Scale (FSS) mean item total score

    Time frame: Through 8 weeks after randomization

  8. Change in the HVLT-R recognition discrimination index T-score

    Time frame: Through 8 weeks after randomization

  9. Change in the Orthostatic Intolerance Questionnaire (OIQ) composite total score

    Time frame: Through 8 weeks after randomization

  10. Change in the total phonemic verbal fluency normed score

    Time frame: Through 8 weeks after randomization

  11. Change in the total semantic fluency normed score

    Time frame: Through 8 weeks after randomization

  12. Change in Trail Making Test (TMT) Part A total scaled score and Part B total scaled score

    Time frame: Through 8 weeks after randomization

  13. Incidence of New Onset Chronic Medical Conditions (NOCMCs)

    Time frame: Through 26 weeks after randomization

  14. Incidence of Solicited Adverse Events

    Time frame: Through 4 days after SGB or Sham

  15. Incidence of treatment-emergent Medically Attended Adverse Events (MAAEs)

    Time frame: Through 26 weeks after randomization

  16. Incidence of treatment-emergent serious adverse events (SAEs)

    Time frame: Through 26 weeks after randomization

  17. Incidence of treatment-emergent unsolicited Adverse Events

    Time frame: Through 12 weeks after randomization

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2029, 28 months later.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 28 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 9, 2026
Primary completionEst.
Apr 9, 2029
CompletionEst.
Apr 9, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07947901
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 9, 2026 (estimated)
Primary completion
Apr 9, 2029 (estimated)
Completion
Apr 9, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

RECOVER Central Contact
Contact
RECOVERTLCHelp@mail.nih.gov
301-496-4000
Anna Bombardieri, MD PhD MSc
study chair · Stanford University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion